tiprankstipranks
Trending News
More News >

Savara price target lowered to $9 from $10 at Citizens JMP

Citizens JMP lowered the firm’s price target on Savara (SVRA) to $9 from $10 and keeps an Outperform rating on the shares. Priority review for Molbreevi could provide a boost to shares in the near-term as management is laser-focused on a potential launch in early 2026, the analyst tells investors in a research note. The firm expects the FDA to accept the submission this month with a PDUFA date possibly by year-end.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1